scholarly journals Organ-saving treatment of invasive bladder cancer

2013 ◽  
Vol 94 (4) ◽  
pp. 501-505
Author(s):  
M E Sitdykova ◽  
A Y Zubkov ◽  
I R Nuriev
Keyword(s):  
Bladder Cancer ◽  
Standard Treatment ◽  
Social Adaptation ◽  
Invasive Bladder Cancer ◽  
Surgical Trauma ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Urological Malignancies ◽  
Muscle Invasive

The review describes the modern approaches to open and endoscopic surgery, chemo- and radiotherapy in organ-saving treatment of invasive bladder cancer. Bladder cancer nowadays ranks the second among urological malignancies. Incidence of bladder cancer in Russia has increased by 58.6% over the past 10 years, with the share of invasive tumors reaching 30%. According to the European Association of Urology guidelines, the radical cystectomy with ureterocolonic diversion is the standard treatment of muscle-invasive bladder cancer. However, the extensive surgical trauma, comorbidities and exhaustion of patients, disability and social adaptation failure as well as the high mortality rate restrict the use of cystectomy. Thereby, taking into account the dynamic development of chemo- and radiotherapy allowing to reduce the recurrence rate, more and more experts are inclined to use organ-saving treatment of invasive bladder cancer. Organ-saving treatment has several advantages: it is less complicated and costly, preserves sexual function, decreases the risk of kidney damage and provides a good quality of life. Still, scanty publications are comparing results of cystectomy and organ-saving treatments of invasive bladder cancer, causing controversial opinions and highlighting the need for further studies.

scholarly journals Management of Non-Muscle-invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations

2019 ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Abstract Background: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42%, 85.42%); stakeholder involvement 41.67% (30.56%, 75.00%); rigour of development 48.96% (27.08%, 65.63%); clarity and presentation 80.56% (75.00%, 86.11%); applicability 34.38% (22.92%, 40.63%) and editorial independence 70.83% (35.42%, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

scholarly journals Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Background Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42, 85.42%); stakeholder involvement 41.67% (30.56, 75.00%); rigour of development 48.96% (27.08, 65.63%); clarity and presentation 80.56% (75.00, 86.11%); applicability 34.38% (22.92, 40.63%) and editorial independence 70.83% (35.42, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

scholarly journals Management of Non-Muscle-invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations

2019 ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Background: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42%, 85.42%); stakeholder involvement 41.67% (30.56%, 75.00%); rigour of development 48.96% (27.08%, 65.63%); clarity and presentation 80.56% (75.00%, 86.11%); applicability 34.38% (22.92%, 40.63%) and editorial independence 70.83% (35.42%, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

scholarly journals Management of Non-Muscle-invasive Bladder Cancer: Quality of Clinical Practice Guidelines and Variations in Recommendations

2019 ◽  
Author(s):  
Jing Zhang ◽  
Yunyun Wang ◽  
Hong Weng ◽  
Danqi Wang ◽  
Fei Han ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Bladder Tumour ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
The Past ◽  
Muscle Invasive

Abstract Background: Bladder cancer (BC) has become a major worldwide public health issue, especially non-muscle-invasive bladder cancer (NMIBC). A flood of related clinical practice guidelines (CPGs) have emerged; however, the quality and recommendations of the guidelines are controversial. We aimed to appraise the quality of the CPGs for NMIBC within the past 5 years and compare the similarities and differences between recommendations for therapies. Methods: A systematic search to identify CPGs for NMIBC was performed using electronic databases (including PubMed, Embase, Web of Science), guideline development organizations, and professional societies from January 12, 2014 to January 12, 2019. The Appraisal of Guidelines Research & Evaluation (AGREE) II instrument was used to evaluate the quality of the guidelines. Intraclass correlation coefficient (ICC) analysis was performed to assess the overall agreement among reviewers. Results: Nine CPGs were included. The overall agreement among reviewers was excellent. The interquartile range (IQR) of scores for each domain were as follows: scope and purpose 69.44% (35.42%, 85.42%); stakeholder involvement 41.67% (30.56%, 75.00%); rigour of development 48.96% (27.08%, 65.63%); clarity and presentation 80.56% (75.00%, 86.11%); applicability 34.38% (22.92%, 40.63%) and editorial independence 70.83% (35.42%, 85.42%). The NICE, AUA, EAU and CRHA/CPAM clinical practice guidelines consistently scored well in most domains. It was generally accepted that the transurethral resection of bladder tumour (TURBT) and intravesical chemotherapy should be performed in the management of bladder cancer. The application of chemotherapy was highly controversial in high risk NMIBC. The courses of BCG maintenance were similar and included 3 years of therapy at full maintenance doses. Conclusions: The quality of NMIBC guidelines within the past 5 years varied, especially regarding stakeholders, rigour and applicability. Despite many similarities, the recommendations had some inconsistencies in the details.

Muscle Invasive Bladder Cancer and Health Related Quality of Life

2021 ◽  
pp. 551-553
Author(s):  
Sanchia S. Goonewardene ◽  
Karen Ventii ◽  
Amit Bahl ◽  
Raj Persad ◽  
Hanif Motiwala ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Health Related Quality ◽  
Muscle Invasive Bladder Cancer ◽  
Related Quality ◽  
Health Related ◽  
Muscle Invasive

scholarly journals Quality of Care Indicators for Muscle-Invasive Bladder Cancer

2011 ◽  
Vol 86 (1) ◽  
pp. 11-18 ◽  
Author(s):  
Catharina A. Goossens-Laan ◽  
Paul J.M. Kil ◽  
Jan A. Roukema ◽  
J.L.H. Ruud Bosch ◽  
Jolanda De Vries
Keyword(s):  
Bladder Cancer ◽  
Quality Of Care ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer

2015 ◽  
Vol 93 (3) ◽  
pp. S23
Author(s):  
K.S. Mak ◽  
A.B. Smith ◽  
A. Eidelman ◽  
R.H. Clayman ◽  
J.S. Cheng ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive ◽  
Long Term Survivors

scholarly journals Quality of life and anxiety in patients with non-muscle invasive bladder cancer: a prospective study

2020 ◽  
Author(s):  
Alexandros Vaioulis ◽  
Konstantinos Bonotis ◽  
Konstantinos Perivoliotis ◽  
Yiannis Kiouvrekis ◽  
Stavros Gavras ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Bladder Cancer ◽  
The State ◽  
Invasive Bladder Cancer ◽  
Physical And Mental Health ◽  
Muscle Invasive Bladder Cancer ◽  
Sf 36 ◽  
Muscle Invasive

Introduction We evaluated anxiety and quality of life (QoL) in patients who were operated for non-muscle invasive bladder cancer (NMIBC) Methods The present study is a prospective analysis of patients with histopathologically confirmed NMIBCs after they were submitted to transurethral resection of the tumour (TURBT). Eligible were all adult patients with a single or multiple NMIBCs. All included patients followed therapy with either BCG or Epirubicin instillations. The SF-36 questionnaire Physical and Mental health aspects were used for QoL assessment. Similarly, the STAI-Y was introduced for the state (STAI-Y1) and trait anxiety (STAI-Y2) evaluation. Results In total, 117 eligible patients were included. Regarding SF-36 Physical a 6 months decrease was followed by an improvement at 12 months. Similarly, an increase of the SF-36 Mental health score was identified. In contrast to STAI-Y2, a long-term reduction of the state anxiety was identified. Preoperative SF-36 Physical was inversely correlated with age, while absence of alcohol was associated with lower mental health. Overall, patient characteristics, habits and the administered treatment did not affect the postoperative QoL and anxiety. Conclusions Patient QoL and anxiety improved during follow up. Although certain characteristics were related to QoL and anxiety, further larger scale studies are required.

Sign in / Sign up

Export Citation Format

Share Document